Camber Pharmaceuticals recalls Atovaquone Oral Suspension USP (750 mg/5 mL) due to Bacillus cereus contamination in repackaged product. This poses a risk of infection from improper use.
Microbial Contamination of Non-Sterile Product: Objectionable organism, identified as Bacillus cereus, found in product during testing of repackaged product.
“Camber Pharmaceuticals Atovaquone Oral Suspension Recall: Microbial Contamination Risk.” GovInfoNow, updated August 18, 2026. https://govinfonow.com/recall/33817-camber-pharmaceuticals-atovaquone-oral-suspension-recall-microbial-contamination-risk. Based on FDA recall #D-0567-2023 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0567-2023%22&limit=1).
The FDA announced on March 13, 2023, that Camber Pharmaceuticals Inc. is recalling Atovaquone Oral Suspension USP due to microbial contamination by Bacillus cereus. Owners should contact the company for a refund.
How to tell if you have it
Brand: Camber Pharmaceuticals
Product: Atovaquone Oral Suspension USP, 750 mg/5 mL, Packaged in 210 mL bottle
NDC#: 31722-629-21
Lot#: E220182
Expiration: 12/31/2023
Quantity: 1568 bottles
The hazard
The recall addresses the presence of Bacillus cereus, an objectionable organism found in the repackaged product during testing. The FDA classified this as a Class I recall, indicating a high risk of adverse health consequences.
Context
GovInfoNow's records show Camber Pharmaceuticals Inc. has two other recalls on record since February 28, 2019. Other recent recalls of similar products include Victory Medical Center Pharmacy Glutathione Vials Recall (July 1, 2026), American Regent Aminocaproic Acid Injection Recall (July 24, 2026), and Zicam Cold Remedy Nasal Swabs Recall (August 10, 2026).
How to tell if you have this one
Check for the product name 'Atovaquone Oral Suspension USP', 750 mg/5 mL, in a 210 mL bottle. The lot number E220182 (expiring 12/31/2023) was manufactured by Hetero Labs Limited in India.
Brand
Camber Pharmaceuticals
Category
Drug
Based on the official FDA remedy
What to do — step by step
Check Product Details
Look for the product name, 750 mg/5 mL concentration, 210 mL bottle, and lot number E220182 on the label.
Where it went and when
Where it was distributed
Distributed nationwide.
Nationwide
Not listed
FDA distribution: “Nationwide in the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA published this recall 2 months after the firm started it.
1Firm started the recall
2FDA classified it Class I
3Published in FDA’s Enforcement Report
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-0567-2023 (March 13, 2023) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0567-2023 to see it in context.
Plain-language summary written by qwen3:4b on August 18, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.